A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR -KDD and Response to Afatinib.

Introduction: Oncogenic mutations in the epidermal growth factor receptor ( EGFR ) occur frequently in patients with lung cancer. These mutations may serve as critical predictive biomarkers in patients with non-small cell lung cancer (NSCLC). Among them, EGFR exon 18-25 kinase domain duplication ( EGFR -KDD) mutations have been identified as a novel EGFR gene subtype in NSCLC. Case Presentation: We reported a rare case of a 59-year-old male diagnosed with adenocarcinoma. A biopsy revealed an EGFR -KDD identified by the next generation sequencing (NGS). Effective treatment outcome has been observed after administration with afatinib. Conclusion: This case highlights that comprehensive NGS technique is valuable in detecting novel genetic mutations in tumors.
(Copyright © 2020 Chen, Li, Wu, Zheng, Wang, Chen, Dong, Xu and Fang.)